Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
PRMT5 inhibition sensitizes B-cell lymphomas to ferroptosis by disrupting the PRMT5-ATF5-SLC7A11 axis, offering a novel therapeutic strategy for relapsed or refractory disease.
A novel statistical model predicts chronic immune thrombocytopenia (ITP) in children at diagnosis, using age, sex, immunoglobulin levels, and lab values, offering early clinical guidance.
In a phase 2 trial, amivantamab did not meet its primary response endpoint in recurrent/metastatic adenoid cystic carcinoma, but most patients achieved stable disease and toxicity was generally manageable.
A single-center retrospective study of 69 pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia reveals that TP53 alterations significantly compromise outcomes following tisagenlecleucel therapy. Pa
Researchers present a pioneering preemptive hematopoietic stem cell transplantation approach for RUNX1-FPD, a hereditary disorder carrying a 35-50% lifetime risk of blood cancer, introducing a shared decision-making framework to guide this
Researchers discovered that loss of GPRC5D, a key immunotherapy target in multiple myeloma, not only confers resistance to targeted therapies but actively promotes cancer cell proliferation and competitive fitness—creating a therapeutic par
A cross-sectional analysis of health technology assessments across G20 nations reveals significant disparities in access to CAR T-cell therapies, with only 48% of approved indications recommended for reimbursement and a median 1.54-year del
Researchers developed PRIME, a parsimonious risk stratification model for pancreatic ductal adenocarcinoma using electronic health record data. Validated across US health systems and the UK Biobank, PRIME retained 19 predictors and achieved
Recent multicenter data indicates that red blood cell exchange transfusion (ET) provides a nearly five-fold reduction in mortality and readmission for patients with severe babesiosis, challenging earlier smaller-scale observations.
The CHRONOS study reveals that third-line therapy for steroid- and ruxolitinib-refractory aGvHD with GI involvement achieves only 36% overall response at Day 28, with concerning durability issues and high mortality rates in this heavily pre
This review explores the breakthrough potential of Bovine Herpesvirus Type 1 (BoHV-1) as an oncolytic agent in Multiple Myeloma, highlighting its ability to induce mitochondrial apoptosis, reprogram the immunosuppressive bone marrow niche,
This review synthesizes evidence that BCR::ABL1 inhibitors induce ribosome collisions and ZAK-dependent apoptosis, highlighting the ribotoxic stress response as a critical pathway for TKI efficacy and a potential target to overcome resistan
Research reveals that Enterococcus faecalis colonization induces MHC-II expression in intestinal epithelial cells during graft-versus-host disease, with a lantibiotic-producing Blautia producta strain demonstrating potential to restore colo
A study of 48 patients with R/R AML treated with revumenib revealed that 52% experienced dynamic immunophenotypic changes. Achieving MRD-negative morphologic remission significantly improved overall survival, highlighting the necessity for
This review analyzes a decade-long nationwide study on TB after Allo-HSCT in France, revealing a 60/100,000 incidence rate, high extrapulmonary involvement, and the critical need for screening patients from high-incidence regions.
This large-scale proteomic analysis identifies 15 novel protein markers for venous thromboembolism, offering new insights into the roles of immunity and extracellular matrix regulation in VTE pathogenesis beyond traditional coagulation path
Researchers have identified oncofetal chondroitin sulfate (ofCS) as a novel target for antibody-drug conjugates in AML. Unlike traditional targets, ofCS is absent in healthy tissues, potentially reducing hematotoxicity and expanding treatme
This study identifies late-onset sex chromosome loss as a critical biomarker for predicting relapse and survival outcomes in patients following sex-mismatched stem cell transplantation.
Recent research identifies BMPR1B and TAZ/TEAD as critical mechanotransduction drivers in relapsed AML. By targeting these pathways, clinicians may overcome the protective effects of bone marrow stiffening and intramedullary pressure, offer
The PHC HOD08 study demonstrates that an 8-week dose-dense modified Stanford V regimen achieves high complete response rates, allowing over 75% of low-risk pediatric Hodgkin lymphoma patients to avoid radiotherapy while maintaining an excep
Open language-specific specialty feeds and department pages.